There areresults for 'Key Finding'
Big pharma is failing to do enough for poor countries
Sophisticated pricing model tailors discounts to population groups
Access planning: How do pharmaceutical companies plan to make new products quickly accessible to patients?
SMS for Life 2.0 expands to further prevent stock-outs of medicines
Access initiatives for cancer products focus on pricing, mainly for small populations
Delivery strategies rank high for Big Pharma, now
Access to medicines - business as usual?
Only a handful of pharma cos are developing the much needed medicines for the poor : ATMI 2018
View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.